NIDDK Provides Additional Data From CyNCh Study Evaluating RP103 in Pediatric NASH at AASLD
November 16, 2015 07:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (NASDAQ:RPTP) today announced researchers have provided additional results from the CyNCh study of RP103 for the treatment...
Raptor Pharmaceutical Provides Topline Results From Phase 2b CyNCh Study Evaluating RP103 in Pediatric Nonalcoholic Steatohepatitis
September 14, 2015 07:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced topline results from the Phase 2b CyNCh study, which did not meet its primary endpoint of...
Raptor Pharmaceutical to Hold Second Quarter 2015 Financial Results Conference Call and Webcast on Thursday, August 6, 2015, at 4:30 p.m. EDT
July 30, 2015 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., July 30, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release second quarter 2015 financial results on Thursday, August 6,...
Foundation for Mitochondrial Medicine Awards Grant to Functional MRI Study of Children With Mitochondrial Disease
May 15, 2012 12:18 ET
|
Foundation for Mitochondrial Medicine
ATLANTA, May 15, 2012 (GLOBE NEWSWIRE) -- The Foundation for Mitochondrial Medicine, a US-based non-profit dedicated to funding research for the treatment of mitochondrial disease, has awarded a...